- Home
- TDS vs CYTK Comparison
TDS vs CYTK Comparison
Compare TDS & CYTK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TDS
- CYTK
- Stock Information
- Founded
- TDS 1968
- CYTK 1997
- Country
- TDS United States
- CYTK United States
- Employees
- TDS N/A
- CYTK N/A
- Industry
- TDS Telecommunications Equipment
- CYTK Biotechnology: Pharmaceutical Preparations
- Sector
- TDS Telecommunications
- CYTK Health Care
- Exchange
- TDS Nasdaq
- CYTK Nasdaq
- Market Cap
- TDS 4.4B
- CYTK 4.6B
- IPO Year
- TDS N/A
- CYTK 2004
- Fundamental
- Price
- TDS $38.16
- CYTK $49.29
- Analyst Decision
- TDS Buy
- CYTK Buy
- Analyst Count
- TDS 2
- CYTK 15
- Target Price
- TDS $52.00
- CYTK $75.57
- AVG Volume (30 Days)
- TDS 1.1M
- CYTK 3.0M
- Earning Date
- TDS 10-31-2025
- CYTK 11-05-2025
- Dividend Yield
- TDS 0.42%
- CYTK N/A
- EPS Growth
- TDS N/A
- CYTK N/A
- EPS
- TDS N/A
- CYTK N/A
- Revenue
- TDS $4,805,000,000.00
- CYTK $85,738,000.00
- Revenue This Year
- TDS N/A
- CYTK $330.96
- Revenue Next Year
- TDS $0.29
- CYTK $73.41
- P/E Ratio
- TDS N/A
- CYTK N/A
- Revenue Growth
- TDS N/A
- CYTK 2635.74
- 52 Week Low
- TDS $22.51
- CYTK $29.31
- 52 Week High
- TDS $42.74
- CYTK $59.39
- Technical
- Relative Strength Index (RSI)
- TDS 44.88
- CYTK 60.02
- Support Level
- TDS $37.72
- CYTK $49.22
- Resistance Level
- TDS $39.85
- CYTK $51.71
- Average True Range (ATR)
- TDS 1.11
- CYTK 2.69
- MACD
- TDS -0.20
- CYTK -0.22
- Stochastic Oscillator
- TDS 12.75
- CYTK 74.05
About TDS Telephone and Data Systems Inc.
Telephone and Data Systems Inc is a diversified telecommunications operator that provides mobile, telephone, and broadband services. The company's segments include UScellular Wireless, UScellular Towers, and TDS Telecom. It generates maximum revenue from the UScellular Wireless segment.
About CYTK Cytokinetics Incorporated
Cytokinetics Inc is a late-stage biopharmaceutical company focused on discovering, developing and commercializing first-in-class muscle activators and next-in-class muscle inhibitors as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. The company develops treatments for diseases such as amyotrophic lateral sclerosis, heart failure, spinal muscular atrophy, and chronic obstructive pulmonary diseases. The treatment is based on small molecules specifically engineered to increase muscle function and contractility. The company is developing muscle-directed investigational medicines that may potentially improve the health span of people with devastating cardiovascular and neuromuscular diseases of impaired muscle function.